These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29768140)

  • 21. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 24. Possible anticompetitive agreements between brand, generic companies to be studied.
    Landis NT
    Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691
    [No Abstract]   [Full Text] [Related]  

  • 25. US branded drug makers pay to prevent generic competition.
    Tanne JH
    BMJ; 2008 Jun; 336(7656):1266-7. PubMed ID: 18535046
    [No Abstract]   [Full Text] [Related]  

  • 26. The king of low cost drugs.
    Kimes M
    Fortune; 2009 Aug; 160(3):88-90, 92. PubMed ID: 19711707
    [No Abstract]   [Full Text] [Related]  

  • 27. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 28. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
    Tu SS; Sarpatwari A
    N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
    [No Abstract]   [Full Text] [Related]  

  • 29. Who Needs XR, LA, SR, XL, ER, or CR?
    Curtiss FR
    J Manag Care Pharm; 2005; 11(9):772-3, 775-6. PubMed ID: 16300421
    [No Abstract]   [Full Text] [Related]  

  • 30. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 33. SaskPharm: a proposal for provincial drug production.
    Meili R
    CMAJ; 2011 Jul; 183(10):1224. PubMed ID: 21609991
    [No Abstract]   [Full Text] [Related]  

  • 34. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 35. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
    Huskamp HA
    Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

  • 39. Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics.
    Son KB
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):541-548. PubMed ID: 31483158
    [No Abstract]   [Full Text] [Related]  

  • 40. [Blocking of generic drugs must be fought].
    Kringlen E
    Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2032. PubMed ID: 24129531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.